Navigation Links
EntreMed to Present at the New York Society of Security Analysts Industry Conference
Date:11/25/2008

ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at www.entremed.com.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

    Ginny Dunn
    Associate Director
    Corporate Communications & Investor Relations
    EntreMed, Inc.
    240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
2. EntreMed Reports Third Quarter 2008 Financial Results
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. EntreMed to Present at BioPartnering Europe Conference
5. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
6. EntreMed Reports Second Quarter 2008 Financial Results
7. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
8. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
9. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Receives Nasdaq Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading designer, ... announced the completion of a significant transaction and partnership that positions Amendia for ... partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing ...
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced ... FDA via 510(k) for sale in the United States. These components expand the ... fusions. With one-level sales beginning in October of 2015, the company has seen ...
(Date:4/28/2016)... 28, 2016 The report "Cryocooler ... Cryocoolers), Service (Technical Support, Product Repairs & Refurbishment, Preventive ... Forecast to 2022", published by MarketsandMarkets, the global market ... 2022, at a CAGR of 7.29% between 2016 and ... and 94 Figures spread through 159 Pages and in-depth ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation ... and Border Protection (CBP) is testing its biometric identity ... San Diego to help identify certain non-U.S. citizens ... . The test, designed to help determine the efficiency and ... began in February and will run until May 2016. ...
Breaking Biology News(10 mins):